News and Activities
Hot Off The Press.
Press Releases
Proteocyte AI continues to expand evidence for Straticyte’s clinical utility and economic value with two new accepted abstracts that will be presented at major oral medicine and oral pathology events in Q2 2025
Toronto, ON; March 5, 2025 –Proteocyte AI—an innovative company that develops and commercializes individualized tests to predict risk of developing cancer, has recently learned that two unique abstracts involving their oral cancer predictive test, Straticyte™, have been accepted to upcoming...
StrataDx & Proteocyte AI Announce Partnership Agreement serving U.S. markets
Toronto, ON; December 13, 2024 – Proteocyte AI—an innovative company that develops and commercializes individualized tests to predict risk of developing cancer, and StrataDx—a clinical and anatomic pathology diagnostic laboratory, announce a new strategic partnership agreement for the U.S. market....
Proteocyte Expands Globally with Distribution Agreement in Turkey
Toronto, ON; December 12, 2024 – Proteocyte Diagnostics announces its partnership with Pharmackt (www.pharmackt.com) to introduce their Oral Cancer Stratification Test, Straticyte, in Turkey for the first time. Pharmackt represents numerous pioneering Molecular Diagnostic companies in the field of...
United Healthcare Now Reimbursing Straticyte™ Test
Patients now have access to a ground-breaking Advanced Diagnostic Laboratory cancer predictive Test for patients at risk of oral cancer. Dallas, TX; October 28, 2024 – Proteocyte announced today that United Healthcare (UHC) is providing coverage for Straticyte™ for National, Regional, and Employer...